UNSPSC 51422361: Prednisolone hemisuccinate

This classification denotes a therapeutic glucocorticoid C25H32O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7080T74ON, chemically known as pregna-1,4-diene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, (11.beta.)-, but more generally known as prednisolone hemisuccinate, which bears US NIH Compound Identifier 4897. European Medicines Agency schedules Prednisolone hemisuccinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35173.

Most nations, for tariff and trade purposes, schedule prednisolone hemisuccinate under HS 29372100 and SITC 54153. As of Q4 2014, PREDNISOLONE HEMISUCCINATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CCC(=O)O)O)CCC4=CC(=O)C=C[C@]34C)O.

UNSPSC 51422361 Prednisolone hemisuccinate is a Commodity code for a specific pharmaceutical active ingredient, but recent state and local contract opportunities show a mismatch between the code's nominal scope and actual purchasing activity. The two recent opportunities posted under this code involve Naloxone and Safe Drug Deactivation Systems procurement (Seminole County, Florida) and a Texas Health and Human Services Commission Request for Information on direct-to-manufacturer prescription programs — neither of which addresses prednisolone hemisuccinate specifically. The code shows minimal relevant recent activity aligned with its stated pharmaceutical product line.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford, and the Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs serving self-insured state employee health plans. The code's activity appears limited to these two opportunities, neither of which reflects prednisolone hemisuccinate procurement — suggesting either tagging inconsistency in the state and local procurement databases or that this Commodity code does not meaningfully track current pharmaceutical purchasing under its nominal scope.